Loading...

CRVC

CVC

CUREVAC NV

(CVAC)

2024 6-K

Show Summary

Summary

Financial Results Released

15 Aug '25

Patent Resolution

7 Aug '25

Voting Results

26 Jun '25

Voting Results Released

24 Jun '25

Acquisition Agreement

16 Jun '25

Filing Summary

12 Jun '25

Annual Meeting Notice

23 May '25

CureVac Financial Update

20 May '25

Financial Results Update

20 May '25

Patent Litigation Update

15 May '25

CureVac Update

10 Apr '25

FDA Approval Announcement

7 Apr '25

Patent Litigation Update

27 Mar '25

Financial Results Update

12 Nov '24

Financial Results Summary

12 Nov '24

CFO Appointment

4 Nov '24

mRNA Conference Update

4 Nov '24

Cancer Vaccine Update

13 Sep '24

Positive Data Release

12 Sep '24

Clinical Data Presentation

9 Sep '24

Financial Update

15 Aug '24

Financial Results Update

15 Aug '24

Phase 1 Study Update

15 Aug '24

Leadership Appointment

15 Aug '24

Patent Litigation Update

11 Jul '24

Collaboration Restructured

3 Jul '24

Annual Meeting Results

26 Jun '24

Annual Meeting Results

24 Jun '24

Influenza Vaccine Update

28 May '24

Shareholder Meeting Notice

24 May '24

Financial Update

23 May '24

CureVac Financial Results

23 May '24

Financial Results Update

24 Apr '24

Influenza Vaccine Study

24 Apr '24

Management Change

24 Apr '24

Strategic Collaboration

16 Apr '24

Flu Vaccine Update

4 Apr '24

CEO Share Purchase

17 Jan '24

Positive Vaccine Data

5 Jan '24

External Links:

SEC

On September 12, 2024, CureVac N.V. announced positive results from GSK’s Phase 2 data of its seasonal influenza mRNA vaccine program. This event is significant for the company as it may enhance its market potential.

AI Assistant

CUREVAC NV

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.